Medical Device Penetration Testing for Cardiovascular Devices
Penetration testing for pacemakers, ICDs, insertable cardiac monitors, and home-monitor backhaul. Pairing, telemetry, and field-update path testing.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Cardiovascular devices - pacemakers, ICDs, CRT-Ds, insertable cardiac monitors, home-monitor transmitters - have the longest deployed lifetimes and the most public history of cybersecurity recalls in the industry. Our pen testing is built around what FDA's CDRH cardiovascular reviewers and CISA have actually called out: programmer-to-device pairing, RF telemetry confidentiality and integrity, home-monitor backhaul, and the long tail of postmarket update channels.
We exercise the in-clinic programmer interface (MedRadio RF on most current devices, BLE on newer patient-side links, inductive on older programmers and wake-up handshakes) for mutual authentication, session-key freshness, and replay resistance. We model the home-monitor as an untrusted bridge: assuming a compromised transmitter, can it issue programming commands or just relay telemetry? Most fail this test on first pass because the device trusts any session that completes pairing. We also test the cellular and Wi-Fi backhaul out of the home monitor - TLS pinning, certificate validation, attestation of the monitor identity to the cloud - and the cloud-side APIs that clinicians use for remote follow-up. Implant-side, we evaluate the firmware update path: signed update enforcement, rollback protection, and behavior under interrupted update (because explant is not an option). The deliverable is a report your design team can act on AND a set of risk-control test evidence your regulatory team can drop into the SPDF and PMA cybersecurity sections.
Layers we exercise in this engagement
The cardiovascular system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this medical device penetration testing.
- 01Clinician portal Tested
- 02Cloud APIs Tested
- 03Cellular / Wi-Fi backhaul Tested
- 04Home monitor Tested
- 05RF / MICS / BLE telemetry Tested
- 06In-clinic programmer Tested
- 07Implant firmware Tested
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Medical Device Penetration Testing engagement, end to end
Four phases, fixed fee, scoped to cardiovascular architecture from kickoff onward.
- 01
Scope + kickoff
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
- 02
Threat-model alignment
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
- 03
Test execution
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
- 04
Reviewer-ready report + retest
eSTAR-format report with findings, CVSS, remediation, and retests until every finding with uncontrolled risk is closed.
What we see in Cardiovascular medical device penetration testing
The patterns we hit in this segment, this service, again and again.
Programmer pairing accepts replayed handshakes
Captured pairing exchange replays successfully against the same implant for the duration of the battery life. Mutual auth is present in spec but not in firmware.
Home monitor → implant trusted as in-clinic programmer
Once paired, the home monitor can issue command opcodes that should be programmer-only. The threat model assumed home monitors were read-only; the firmware did not enforce it.
Cellular backhaul lacks certificate pinning
Home-monitor MQTT/HTTPS endpoints validate CA chain but not specific cert. A network-position attacker with a CA-trusted cert can MITM telemetry and acks.
Cloud follow-up API leaks device identifiers cross-account
Predictable IDOR on /devices/{serial}/episodes returns ECG strips for any account when caller is authenticated but not authorized. Classic broken-object-level authorization.
Firmware downgrade allowed via legacy update tool
Field-service update tool from a previous generation still accepts older signed bundles. Attacker with physical/programmer access can downgrade to a known-vulnerable build.
Public cardiovascular cybersecurity history
Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about in this segment - and what our scope is built to cover.
- CISA + FDA·2018
Medtronic CareLink 2090 / 29901 programmer software-update vulnerability
Software-update integrity gap allowed a network-positioned attacker to alter programmer software, indirectly affecting implant programming. FDA-issued safety communication followed.
Advisory - FDA·2017
Abbott (St. Jude) Merlin@home transmitter firmware update
OTA firmware update issued to address authentication weaknesses on the home transmitter that could permit unauthorized programming commands to implants.
Advisory - CISA + FDA·2019
Medtronic Conexus telemetry protocol
Conexus RF protocol lacked encryption and authentication, allowing nearby attackers to read or modify implant communications. Drove industry-wide expectations on telemetry confidentiality and integrity.
Advisory
"Blue Goat Cyber helped us navigate our first end-to-end cybersecurity testing for our wearable medical device. Their communication was excellent, their timeline exceeded expectations, and their report helped us achieve FDA clearance without any additional questions. It was a truly seamless experience."
Standard Medical Device Penetration Testing deliverables
The same deliverables the parent Medical Device Penetration Testing service ships with - tuned to your cardiovascular architecture.
- Device, firmware, and embedded testing - hardware teardown, JTAG/UART/SPI bus access, firmware extraction and reverse engineering, and exploitation of the secure boot, debug, and update paths. Done by operators who have tested infusion pumps, monitors, surgical robots, and implantables.
- Companion app and cloud API coverage - iOS/Android binary analysis, BLE pairing/GATT attacks, REST/MQTT/gRPC fuzzing, authentication and authorization testing, and tenant-isolation checks. We test the device as patients and clinicians actually use it, not in isolation.
- FDA-ready penetration test reports - executive summary, methodology, CVSS-scored findings tied to your threat model, reproduction steps, and a signed Letter of Attestation covering tester independence, scope, methods, and results. Reviewer-ready, not a generic IT security PDF.
- Remediation guidance and re-test included - written fix recommendations per finding, engineer-to-engineer support during remediation, and unlimited re-tests of fixed issues inside the fixed fee. You leave with a clean report, not a list of open items.
What lands in your eSTAR submission
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
- Device, firmware, and embedded testing - hardware teardown, JTAG/UART/SPI bus access, firmware extraction and reverse engineering, and exploitation of the secure boot, debug, and update paths. Done by operators who have tested infusion pumps, monitors, surgical robots, and implantables.
- Companion app and cloud API coverage - iOS/Android binary analysis, BLE pairing/GATT attacks, REST/MQTT/gRPC fuzzing, authentication and authorization testing, and tenant-isolation checks. We test the device as patients and clinicians actually use it, not in isolation.
- FDA-ready penetration test reports - executive summary, methodology, CVSS-scored findings tied to your threat model, reproduction steps, and a signed Letter of Attestation covering tester independence, scope, methods, and results. Reviewer-ready, not a generic IT security PDF.
- Remediation guidance and re-test included - written fix recommendations per finding, engineer-to-engineer support during remediation, and unlimited re-tests of fixed issues inside the fixed fee. You leave with a clean report, not a list of open items.
Standards that apply
The Cardiovascular baseline, plus the call-outs that matter for medical device penetration testing in this segment.
Segment-specific call-outs
ANSI/AAMI/IEC TIR60601-4-5
Cardiac device reviewers expect this referenced in your security risk-control evidence - particularly for programmer↔device interfaces.
FDA Postmarket Cybersecurity (524B + Feb 3, 2026 final guidance)
10-15 year fleets demand SBOM monitoring + a documented coordinated vulnerability disclosure program. Pen test scope must include the postmarket update path, not just the as-shipped device.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Hospital enterprise IT network penetration testing
- Clinical efficacy or human-factors validation
- Physical security of manufacturing sites
- Source-code review (unless explicitly added as a separate engagement)
Medical Device Penetration Testing for Cardiovascular - FAQs
The questions buyers in this segment actually ask before scoping a medical device penetration testing engagement.
Go deeper on Cardiovascular and premarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
The most common high- and critical-severity findings we surface in medical device penetration tests, what each one looks like in the field, and how to fix it before your FDA submission.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
Medical device cybersecurity at each study stage: rodent, large animal, primate, and human trials, and what the FDA expects before your IDE and marketing submission.
What a medical device security advisor does after FDA clearance: keeping the threat model and SBOM current, rating vulnerabilities, and answering hospitals.
Threat modeling AI-enabled medical devices: how to add the model, training pipeline, and updates to your threat model, with a worked example of a fictional AI dosing advisor.
Other engagements for Cardiovascular
Teams in this segment commonly bundle these alongside medical device penetration testing.
Keep going
Scope a Medical Device Penetration Testing engagement for your cardiovascular program.
A 30-minute call with a senior engineer who has done this in cardiovascular before - not a sales rep.